Call +1 858 457-8383 Fax +1 858 457-8484

Nampt (Visfatin/PBEF) (human) ELISA Kit

Replaced by the product: AG-45A-0006Y
AG-45A-0006EK-KI01 96 wells $660.00
AG-45A-0006TP-KI01 2 x 96 wells $1,050.00
AG-45A-0006PP-KI01 5 x 96 wells $2,100.00
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +1 858 457-8383
Fax +1 858 457-8484
Contact Us!

Additional Information

Product Data
Synonyms Nicotinamide Phosphoribosyltransferase; PBEF1; Pre-B Cell Colony Enhancing Factor 1
Properties
Application Set Quantitative ELISA
Specificity Detects human Nampt. Weakly cross-reacts (<15%) with mouse Nampt and rat Nampt. Does not cross-react with human adiponectin, human resistin, human vaspin or human RBP4. Has been shown to specifically detect the physiologically relevant Nampt dimer in human serum samples.
Crossreactivity Human
Quantity 1 x 96 wells
2 x 96 wells (Twin Plex)
5 x 96 wells (Penta Plex)
Sensitivity 30pg/ml
Range 0.125 to 8ng/ml
Sample Type Serum
Assay Type Sandwich
Detection Type Colorimetric
Other Product Data Note: Does not work with plasma samples.
Product Type Kit
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice After standard reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Plate and reagents should reach room temperature before use.
Documents
Manual Download Document Download
Manual TwinPlex Download Document Download
Manual PentaPlex Download Document Download
MSDS Download Document Download
Related Products

Product Description

Nicotinamide phosphoribosyltransferase (Nampt; pre-B cell colony-enhancing factor; PBEF; Visfatin) is an 52kDA adipokine secreted by adipose tissue and involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). Two forms of Nampt exist, an intracellular form (iNampt) and an extracellular form (eNampt). While the function of iNampt as an essential and rate-limiting NAD+ biosynthetic enzyme is well established, the physiological role of eNampt is still a matter of debate. It has been shown that Nampt expression is increased in different diseases, like diabetes, obesity, fetal growth retardation, sepsis, inflammatory bowel disease, Crohn’s disease and rheumatoid arthritis. Furthermore, Nampt might be a marker of pre-eclampsia and of endothelial health.

Product References

  1. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway: T. Yonezawa, et al.; FEBS Lett. 580, 6635 (2006)
  2. Molecular characteristics of serum visfatin and differential detection by immunoassays: A. Koerner, et al.; J. Clin. Endocrinol. Metab. 92, 4783 (2007)
  3. Serum levels of the adipokine visfatin are increased in pre-eclampsia: M. Fasshauer, et al.; Clin. Endocrinol. 69, 69 (2008)
  4. Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study: R. Retnakaran, et al.; Clin. Endocrinol. 69, 885 (2008)
  5. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery: M. M. Swarbrick, et al.; Diabetologia 51, 1901 (2008)
  6. Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis: M. Ziegelmeier, et al.; Metabolism 57, 1414 (2008)
  7. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy: A.A. Alghasham & Y.A. Barakat; Saudi Med. J. 29, 185 (2008)
  8. Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function: M. Reimann, et al.; Obesity 17, 2210 (2009)
  9. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis: F. Lovren, et al.; Am. J. Physiol. Endocrinol. Metab. 296, E1440 (2009)
  10. Circulating visfatin in chronic obstructive pulmonary disease: X. Liu, et al.; Nutrition 25, 373 (2009)
  11. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue: B. Telejko, et al.; Diabetes Res. Clin. Pract. 84, 68 (2009)
  12. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers: S. Bo, et al.; Nutr. Metab. Cardiovasc. Dis. 19, 423 (2009)
  13. Release of 12 Adipokines by Adipose Tissue, Nonfat Cells, and Fat Cells From Obese Women: J. N. Fain, et al.; Obesity (Silver Spring) 18, 890 (2009)
  14. Plasma visfatin and ghrelin response to prolonged sculling in competitive male rowers: J. Jurimae, et al.; Med. Sci. Sports Exerc. 41, 137 (2009)
  15. Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue: B. Telejko, et al.; Diabetes Res. Clin. Pract. 84, 68 (2009)
  16. Adipokines and systemic lupus erythematosus: relationship with metabolic syndrome and cardiovascular disease risk factors: M. Vadacca, et al.; J. Rheumatol. 36, 295 (2009)
  17. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol: K. D. Nusken, et al.; Nephrol. Dial. Transplant. 24, 2832 (2009)
  18. Alteration of adipokines during peripheral blood stem cell mobilization induced by granulocyte colony-stimulating factor: Y. Tanaka, et al.; J. Clin. Apheresis 24, 205 (2009)
  19. Peritoneal fluid adipokines: ready for prime time? R. Wiest, et al.; Eur. J. Clin. Invest. 39, 219 (2009)
  20. Relationship between genotype and serum levels of adipokines and bone mineral density in type 2 diabetes mellitus patients: K. Mirzaei, et al.; Iran. J. Diab. Lip. Dis. 8, 77 (2009)
  21. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer: T.E. Nakajima, et al.; J. Gastroenterol. 44, 685 (2009)
  22. Variation in the visfatin gene may alter the required dosage of oral antidiabetic agents in type 2 diabetic patients: K. Mirzaei, et al.; Iran. J. Diab. Lip. Dis. 8, 87 (2009)
  23. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo: G. Sommer, et al.; Obesity 18, 1486 (2010)
  24. A 12-week regimen of caloric restriction improves levels of adipokines and pro-inflammatory cytokines in Korean women with BMIs greater than 23 kg/m2: I.S. Lee, et al.; Inflamm. Res. 59, 399 (2010)
  25. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes: A. Garten, et al.; BBRC 391, 376 (2010)
  26. The relationship between visfatin and metabolic syndrome in postmenopausal women: J.H. Kim, et al.; Maturitas 67, 67 (2010)
  27. Transcriptome analysis of monocyte-HIV interactions: R. Van den Bergh, et al.; Retrovirology 7, 53 (2010)
  28. Adipokines and cardiometabolic function: How are they interlinked?: A.E. Schutte, et al.; Regul. Pept. 164, 133 (2010)
  29. A 12-week regimen of caloric restriction improves levels of adipokines and pro-inflammatory cytokines in Korean women with BMIs greater than 23 kg/m2: I.S. Lee, et al.; Inflamm. Res. 59, 399 (2010)
  30. Splanchnic concentrations and postprandial release of visceral adipokines: R. Wiest, et al.; Metabolism 59, 664 (2010)
  31. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer: T.E. Nakajima, et al.; Cancer Sci. 101, 1286 (2010)
  32. Effect of green tea extract on bone turnover markers in type 2 diabetic patients; A double- blind, placebo-controlled clinical trial study: K. Mirzaei, et al.; DARU J. Pharm. Sci. 17 (Suppl 1), 38 (2010)
  33. Adipocytokines and bone mineral density in adolescent female athletes: R. Gruodyte, et al.; Acta Paediatr. 99,1879 (2010)
  34. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity: A. Esteghamati, et al.; Diabetes Res. Clin. Pract. 91, 154 (2011)
  35. Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables: J. Jurimae, et al.; JPEM 24, 419 (2011)
  36. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism: G.A. Martos-Moreno, et al.; Int. J. Obes. (Lond) 35, 1355 (2011)
  37. Admission Visfatin Levels Predict Pancreatic and Peripancreatic Necrosis in Acute Pancreatitis and Correlate With Clinical Severity: A. Schaeffler, et al.; Am. J. Gastroenterol. 106, 957 (2011)
  38. Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA): G. Aust, et al.; Clin. Chim. Acta. 412, 1195 (2011)
  39. The effect of omega-3 on the serum visfatin concentration in patients with type II diabetes: H. Hajianfar, et al.; JRMS 16, 490 (2011)
  40. Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis: K.A. Lee & M.N. Gong; Chest 140, 382 (2011)
  41. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome: T.K. Lajunen, et al.; Eur. J. Clin. Invest. 42, 321 (2011)
  42. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells: S. Ninomiya, et al.; Cancer Prev. Res. (Phila) 4, 2092 (2011)
  43. Type 2 diabetes and lipoprotein metabolism affect LPS-induced cytokine and chemokine release in primary human monocytes: M. Bala, et al.; Exp. Clin. Endocrinol. Diabetes 119, 370 (2011)
  44. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM: S. Mohammadi, et al.; Diab. Metab. Syndr: Clin. Res. Rev. 5, 71 (2011)
  45. Visfatin is secreted into the breast milk and is correlated with weight changes of the infant after the birth: J. Bienertova-Vasku, et al.; Diabetes Res. Clin. Pract. 96, 355 (2012)
  46. Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines: X. Terra, et al.; Clin. Endocrinol. (Oxf.) 77, 691 (2012)
  47. Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy: N. Rezvan, et al.; Arch. Gynecol. Obstet. 285, 1257 (2012)
  48. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus: S. Akbarzadeh, et al.; Diabetes Res. Clin. Pract. 95, 132 (2012)
  49. Extracellular ATP induces P2X7-dependent nicotinamide phosphoribosyltransferase release in LPS-activated human monocytes: E. Schilling & S. Hauschildt; Innate Immun. 18, 738 (2012)
  50. The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis: A. Esteghamati, et al.; J. Cardiovasc. Transl. Res. 5, 541 (2012)
  51. The effects of omega-3 on blood pressure and the relationship between serum visfatin level and blood pressure in patients with type II diabetes: M.J. Hosseinzadeh-Attar, et al.; ARYA Atheroscler. 8, 1 (2012)
  52. Association of sleep onset of acute coronary syndrome with sleep apnea syndrome and abnormal diurnal variation of hemostasis and adipokine levels: Y. Yano, et al.; Blood Coagul. Fibrinolysis 23, 590 (2012)
  53. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women: M. Tohidi, et al.; Bone 51, 876 (2012)
  54. Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls: H. Hajianfar, et al.; Int. J. Prev. Med. 3, 326 (2012)
  55. Effect of substituting saturated with monounsaturated fatty acids on serum visfatin levels and insulin resistance in overweight women: A randomized cross-over clinical trial: F. Haghighatdoost, et al.; Int. J. Food Sci. Nutr. 63, 772 (2012)
  56. Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease: T. Auguet, et al.; Clin. Biochem. 46, 202 (2013)
  57. Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery: Z. Karbaschian, et al.; Endocrine 44, 114 (2013)
  58. Associations of metabolic factors and adipokines with pain in incipient upper extremity soft tissue disorders: a cross-sectional study: M. Rechardt, et al.; BMJ Open 3, e003036 (2013)
  59. Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage: S.J. Gu, et al.; Clin. Chim. Acta. 425, 85 (2013)
  60. Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects: M.J. Hosseinzadeh-Attar, et al.; Obes. Facts 6, 193 (2013)
  61. Expression and regulation of nampt in human islets: K. Kover, et al.; PLoS One 8, e58767 (2013)
  62. Visfatin as a Novel Mediator Released by Inflamed Human Endothelial Cells: T. Romacho, et al.; PLoS One 8, e78283 (2013)
  63. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease: S. Emamgholipour, et al.; PLoS One 8, e76555 (2013)
  64. Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects: Z. Goktas, et al.; Mediators Inflamm. 2013, 861496 (2013)
  65. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis: M.C. Laiguillon, et al.; Arthritis Res. Ther. 16, R38 (2014)
  66. Identification of adipokine clusters related to parameters of fat mass, insulin sensitivity and inflammation: G. Flehmig, et al.; PLoS One 9, e99785 (2014)
<b>Standardcurve</b>
Standardcurve
No reviews for this product yet.